8-K: Agenus Reports Positive Clinical Trial Results and Financial Update for 2023

Agenus announced promising clinical trial results for its BOT/BAL combination therapy across multiple cancer types, along with its fourth quarter and full year 2023 financial results.

Summary

• Agenus reported its fourth quarter and full year 2023 financial results, including revenue of $156 million for the year and a net loss of $257 million, or $0.69 per share.
• The company's BOT/BAL combination therapy showed a 24% response rate in refractory colorectal cancer patients with non-active liver metastases, compared to a 1-6.1% response rate with standard therapies.
• Agenus completed enrollment in a Phase 2 trial for BOT/BAL in refractory colorectal cancer with 230 patients, with topline data expected in the second half of 2024.
• In neoadjuvant colorectal cancer, 100% of MSI-H patients experienced major pathological responses, and 67% of MSS patients had significant tumor shrinkage.
• In metastatic pancreatic cancer, significant tumor marker reductions were observed in 4 of 5 patients treated with BOT in combination with gemcitabine+nab-paclitaxel.
• Agenus received a $25 million milestone payment from BMS and is exploring options to monetize assets and royalties, potentially yielding $100-200 million in cash proceeds.
• The company anticipates being funded through 2024 and is in discussions with potential partners for co-development and co-commercialization of BOT/BAL.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and financial updates, with a clear path to potential revenue generation. The high response rates and survival data are very encouraging, although the company is still loss making and needs to raise capital.

Positives

• The Fast Track designation from the FDA for BOT/BAL in metastatic, refractory colorectal cancer could expedite the approval process.
• The 24% ORR in refractory colorectal cancer with BOT/BAL is significantly higher than the 1-6.1% seen with standard therapies.
• The 74% 12-month overall survival rate in refractory colorectal cancer is very promising.
• The 100% major pathological response rate in MSI-H neoadjuvant colorectal cancer patients is exceptional.
• The 56% ORR and 89% disease control rate in refractory non-small cell lung cancer with BOT/BAL is very encouraging.
• The $25 million milestone payment from BMS strengthens the company's financial position.
• The potential to raise $100-200 million through asset monetization and project financing provides additional financial flexibility.

Negatives

• Agenus incurred a net loss of $257 million for the full year 2023.
• Grade 3 treatment-related diarrhea/colitis occurred in approximately 14% of patients treated with BOT/BAL.
• The company ended the year with a cash balance of $76.1 million, which may require further capital raising.

Risks

• The clinical trials for BOT/BAL are still ongoing, and the results may not be as positive as the preliminary data suggests.
• The company's financial losses are significant, and it may need to raise additional capital to fund its operations.
• The company is dependent on the success of its BOT/BAL program, and any setbacks could have a significant impact on its future.
• The company faces competition from other companies developing cancer therapies.
• The company's ability to monetize assets and royalties is not guaranteed.

Future Outlook

Agenus anticipates being funded through 2024 and expects topline data from the Phase 2 study in refractory colorectal cancer in the second half of 2024. The company is also pursuing potential partnerships to expand cash resources.

Management Comments

• Garo Armen, Ph.D., Chief Executive Officer, stated that Agenus is focused on pursuing accelerated approval for BOT/BAL in metastatic, refractory colorectal cancer.
• Management is pursuing multiple strategies to capitalize the company through this important path in our efforts to bring BOT and BOT/BAL to the forefront of solid tumor cancer treatment.
• Management's vision is to maximize BOT's utility to benefit patients in combination with other immune therapies as well as current standards of care for patients with both early and late-stage tumors.

Industry Context

The announcement highlights Agenus's progress in the competitive immuno-oncology space, where companies are racing to develop effective treatments for various cancers. The positive results for BOT/BAL in multiple cancer types position Agenus as a potential leader in the field.

Comparison to Industry Standards

• The 24% ORR for BOT/BAL in refractory colorectal cancer is significantly higher than the 1-6.1% response rate typically seen with standard of care therapies, such as those reported in the Prager et al. NEJM 2023 and Grothey et al. Lancet 2013 studies.
• The 74% 12-month overall survival rate in refractory colorectal cancer is also very promising compared to historical data for this patient population.
• The 100% major pathological response rate in MSI-H neoadjuvant colorectal cancer patients is exceptional and compares favorably to other neoadjuvant therapies.
• The 56% ORR and 89% disease control rate in refractory non-small cell lung cancer with BOT/BAL is competitive with other novel therapies in this space.
• The 30% ORR and 60% disease control rate in 2L+ Melanoma is also competitive with other novel therapies in this space.

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical trial results and potential for future revenue growth.
• Employees may be motivated by the company's progress and potential for success.
• Patients may benefit from the development of new and effective cancer therapies.
• Potential partners may be interested in collaborating with Agenus on the development and commercialization of BOT/BAL.

Next Steps

• Agenus expects topline data from the Phase 2 study in refractory colorectal cancer in the second half of 2024.
• The company plans to prioritize neoadjuvant development and is evaluating study designs for subsequent pivotal trials.
• Agenus is in active discussions with several potential biopharma partners for potential co-development and co-commercialization of BOT/BAL.
• The company will continue to advance discussions on monetizing non-strategic assets, royalty monetization, and project financing.

Key Dates

Keywords

Botensilimab, Balstilimab, Colorectal Cancer, Immunotherapy, Cancer, Clinical Trials, Metastatic, FDA Fast Track, Oncology, Biopharma